Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares Sold by Walleye Capital LLC

Walleye Capital LLC trimmed its stake in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 32.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,500 shares of the company’s stock after selling 21,448 shares during the quarter. Walleye Capital LLC’s holdings in Checkpoint Therapeutics were worth $142,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in shares of Checkpoint Therapeutics during the third quarter worth about $30,000. SBI Securities Co. Ltd. acquired a new stake in Checkpoint Therapeutics during the fourth quarter valued at approximately $32,000. PUREfi Wealth LLC bought a new position in Checkpoint Therapeutics during the 4th quarter worth approximately $32,000. Bartlett & CO. Wealth Management LLC grew its position in shares of Checkpoint Therapeutics by 375.0% in the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 19,000 shares of the company’s stock worth $61,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Checkpoint Therapeutics in the 4th quarter valued at approximately $64,000. 22.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CKPT shares. HC Wainwright restated a “neutral” rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th. Lake Street Capital restated a “hold” rating and issued a $4.10 price target (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a research report on Monday, March 31st.

Checkpoint Therapeutics Price Performance

NASDAQ:CKPT opened at $4.10 on Friday. The firm has a market capitalization of $343.43 million, a P/E ratio of -2.23 and a beta of 1.21. The business has a 50 day simple moving average of $3.70 and a 200 day simple moving average of $3.52. Checkpoint Therapeutics, Inc. has a 12-month low of $1.38 and a 12-month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The firm had revenue of $0.04 million for the quarter. Research analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 10,331 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.15, for a total transaction of $32,542.65. Following the completion of the transaction, the chief executive officer now owns 3,775,019 shares in the company, valued at approximately $11,891,309.85. The trade was a 0.27 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO William Garrett Gray sold 12,322 shares of the firm’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total value of $49,904.10. Following the transaction, the chief financial officer now directly owns 1,446,322 shares in the company, valued at $5,857,604.10. This trade represents a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 121,086 shares of company stock worth $446,879. Insiders own 2.10% of the company’s stock.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.